Laïla‐Aïcha Hanafi

5.9k total citations · 5 hit papers
24 papers, 4.3k citations indexed

About

Laïla‐Aïcha Hanafi is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Laïla‐Aïcha Hanafi has authored 24 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Immunology and 4 papers in Genetics. Recurrent topics in Laïla‐Aïcha Hanafi's work include CAR-T cell therapy research (16 papers), Biosimilars and Bioanalytical Methods (4 papers) and Tryptophan and brain disorders (4 papers). Laïla‐Aïcha Hanafi is often cited by papers focused on CAR-T cell therapy research (16 papers), Biosimilars and Bioanalytical Methods (4 papers) and Tryptophan and brain disorders (4 papers). Laïla‐Aïcha Hanafi collaborates with scholars based in United States, Canada and Japan. Laïla‐Aïcha Hanafi's co-authors include Cameron J. Turtle, Stanley R. Riddell, David G. Maloney, Daniel Li, Kevin A. Hay, Sindhu Cherian, Xueyan Chen, Susanna Harju-Baker, Juliane Gust and Dominic W. Chung and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Laïla‐Aïcha Hanafi

24 papers receiving 4.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

2017 948 citations Juliane Gust, Kevin A. Hay et al. Cancer Discovery profile →
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

2017 775 citations Kevin A. Hay, Laïla‐Aïcha Hanafi et al. Blood profile →
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

2016 741 citations Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. Science Translational Medicine profile →
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

2017 485 citations Cameron J. Turtle, Kevin A. Hay et al. Journal of Clinical Oncology profile →
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

2017 446 citations Germán G. Gornalusse, Roli K. Hirata et al. Nature Biotechnology profile →

Peers

Laïla‐Aïcha Hanafi

ONCOL

IMMUN

GENET

Marco L. Davila United States

Bianca Santomasso United States

Theodoros Giavridis United States

Zhiqiang Wu China

Stefanie R. Bailey United States

Tiejuan Mi United States

Judith Feucht Germany

Rosalie M. Sterner United States

Clare Y. Slaney Australia

Stephanie L. Goff United States

Marco L. Davila United States

Laïla‐Aïcha Hanafi

3.7k ×1.1

ONCOL

1.2k ×1.0

1.3k ×1.2

IMMUN

936 ×0.9

1.1k ×1.2

GENET

Citations per year, relative to Laïla‐Aïcha Hanafi Laïla‐Aïcha Hanafi (= 1×) peers Marco L. Davila

Countries citing papers authored by Laïla‐Aïcha Hanafi

Since Specialization

Citations

This map shows the geographic impact of Laïla‐Aïcha Hanafi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laïla‐Aïcha Hanafi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laïla‐Aïcha Hanafi more than expected).

Fields of papers citing papers by Laïla‐Aïcha Hanafi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laïla‐Aïcha Hanafi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laïla‐Aïcha Hanafi. The network helps show where Laïla‐Aïcha Hanafi may publish in the future.

Co-authorship network of co-authors of Laïla‐Aïcha Hanafi

This figure shows the co-authorship network connecting the top 25 collaborators of Laïla‐Aïcha Hanafi. A scholar is included among the top collaborators of Laïla‐Aïcha Hanafi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laïla‐Aïcha Hanafi. Laïla‐Aïcha Hanafi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanafi, Laïla‐Aïcha, Angélique Bellemare‐Pelletier, Katia Hamelin, et al.. (2021). MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy. PLoS ONE. 16(12). e0261987–e0261987. 6 indexed citations

Sheih, Alyssa, Valentin Voillet, Laïla‐Aïcha Hanafi, et al.. (2020). Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications. 11(1). 219–219. 177 indexed citations

Sarikonda, Ghanashyam, Mélissa Mathieu, Anil Pahuja, et al.. (2020). Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry Part B Clinical Cytometry. 100(1). 79–91. 25 indexed citations

Litwin, Virginia, et al.. (2020). Strategies for successful monitoring of CAR T-cells by flow cytometry. Cytotherapy. 22(5). S130–S130. 3 indexed citations

Gust, Juliane, Kevin A. Hay, Laïla‐Aïcha Hanafi, et al.. (2017). Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery. 7(12). 1404–1419. 948 indexed citations breakdown →

Bhattacharyya, Abir, Laïla‐Aïcha Hanafi, Alyssa Sheih, et al.. (2017). Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(2). 242–251. 65 indexed citations

Gornalusse, Germán G., Roli K. Hirata, Sarah E. Funk, et al.. (2017). HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nature Biotechnology. 35(8). 765–772. 446 indexed citations breakdown →

Turtle, Cameron J., Kevin A. Hay, Laïla‐Aïcha Hanafi, et al.. (2017). Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy. Blood. 130(Suppl_1). 805–805. 2 indexed citations

Turtle, Cameron J., Kevin A. Hay, Juliane Gust, et al.. (2017). Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.. Journal of Clinical Oncology. 35(15_suppl). 3020–3020. 15 indexed citations

10.

Turtle, Cameron J., Laïla‐Aïcha Hanafi, Daniel Li, et al.. (2016). CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. Blood. 128(22). 56–56. 12 indexed citations

11.

Turtle, Cameron J., Kevin A. Hay, Laïla‐Aïcha Hanafi, et al.. (2016). Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose. Blood. 128(22). 1852–1852. 8 indexed citations

12.

Turtle, Cameron J., Laïla‐Aïcha Hanafi, Carolina Berger, et al.. (2016). Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.. Journal of Clinical Oncology. 34(15_suppl). 102–102. 21 indexed citations

13.

Turtle, Cameron J., Laïla‐Aïcha Hanafi, Carolina Berger, et al.. (2016). Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine. 8(355). 355ra116–355ra116. 741 indexed citations breakdown →

14.

Turtle, Cameron J., Carolina Berger, Daniel Sommermeyer, et al.. (2015). Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood. 126(23). 184–184. 59 indexed citations

15.

Turtle, Cameron J., Carolina Berger, Daniel Sommermeyer, et al.. (2015). Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.. Journal of Clinical Oncology. 33(15_suppl). 3006–3006. 13 indexed citations

16.

Hanafi, Laïla‐Aïcha, Dominique Gauchat, Jessica Godin-Ethier, et al.. (2014). Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism. PLoS ONE. 9(6). e99211–e99211. 24 indexed citations

17.

Pallet, Nicolas, Isabelle Sirois, Christina Bell, et al.. (2013). A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells. PROTEOMICS. 13(7). 1108–1120. 93 indexed citations

18.

Godin-Ethier, Jessica, et al.. (2011). IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Molecular Immunology. 49(1-2). 253–259. 28 indexed citations

19.

Godin-Ethier, Jessica, Laïla‐Aïcha Hanafi, Ciriaco A. Piccirillo, & Réjean Lapointe. (2011). Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. Clinical Cancer Research. 17(22). 6985–6991. 320 indexed citations

20.

Godin-Ethier, Jessica, Sandy Pelletier, Laïla‐Aïcha Hanafi, et al.. (2009). Human Activated T Lymphocytes Modulate IDO Expression in Tumors through Th1/Th2 Balance. The Journal of Immunology. 183(12). 7752–7760. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact